Dopamine: The Forgotten Felon in Type 2 Diabetes
Sanjay Kalra, Bharti Kalra, Navneet Agrawal and Satish Kumar
Affiliation: Bharti Hospital, Kunjpura Road, Karnal, 132001, Haryana, India.
Keywords: Type 2 diabetes, obesity, bromocriptine, dopamine, dopaminergic agents, epidemic, insulin, Ominous Octet, gastrointestinal tract, kidney, brain, neurohormones, neurotransmitters, substantia nigra, ventral tegmental area, hypo-thalamus, mesolimbic path-ways, tonic, sexual gratification, Syrian hamsters, swine, drugs, pleiotropic, antipsychotics act, ergot alkaloids, Parkinson's disease, prolactinoma, acromegaly, gynaecological indications, peripartum cardiomyopathy, serum triglycerides, cyclosporine, plasma glucose, hypocaloric diet, placebo, syncopal migraine, lactation, giddiness
This paper reviews recent patents and development related to bromocriptine and other dopaminergic agents, being used or suggested for use in the management of diabetes. The article discusses the contribution of dopaminergic pathways to glucose, energy and weight homeostasis. The mechanism of action of bromocriptine, its pharmacological properties, efficacy, safety and tolerability are assessed. The article also covers recent patents which may be utilized to improve the efficiency and tolerability of dopamine-based therapy in diabetes mellitus.
Rights & PermissionsPrintExport